<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02621489</url>
  </required_header>
  <id_info>
    <org_study_id>BY2015</org_study_id>
    <nct_id>NCT02621489</nct_id>
  </id_info>
  <brief_title>Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects</brief_title>
  <acronym>Rebuild</acronym>
  <official_title>Effects on Re-endothelialisation With Bydureon Treatment Add on to Insulin Versus Insulin Alone, Both in Combination With Metformin in Type 2 Diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to use Exenatide long-acting release (LAR) [Bydureon] to minimize
      vascular remodeling and neointima formation after Percutaneous Coronary Intervention (PCI)
      and to accelerate stent endothelialisation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exenatide LAR will be given as a once-weekly (s.c.) dose of Bydureon (2 mg) add on to Insulin
      in combination with Metformin. If patients are Insulin naïve (both groups) an initial dose of
      10U (s.c.) at bedtime will be started, and further up-titrated to achieve a fP-glucose levels
      at 6 mmol/l. Standard care for post myocardial infarction will be given after PCI.

      Primary objectives:

      To test whether Bydureon, add on to Insulin Neutral Protamine Hagedorn (NPH) + Metformin, is
      superior vs. Insulin NPH + Metformin alone, in covered stent struts

      Secondary objectives:

      To test whether Bydureon, add on to Insulin NPH + Metformin, is superior vs. Insulin NPH +
      Metformin alone: in cardiac and endothelial functions
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The degree of non-covered stent struts by Bydureon add on to Insulin over that of Insulin as analyzed by optical coherence tomography (OCT).</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fractional Flow Reserve (FFR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>FFR is a unitless index calculated as the ratio between distal coronary and aortic pressure during maximum hyperemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary Flow velocity Reserve (CRF)</measure>
    <time_frame>12 weeks</time_frame>
    <description>CFR is a unitless index calculated as the ratio between the the mean transit time recorded at maximum hyperemia and at baseline using the thermodilution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index of Microcirculatory Resistance (IMR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>IMR is a unitless index calculated by dividing the mean distal coronary pressure by the inverse of the mean transit time recorded using the thermodilution technique during maximum hyperemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional flow reserve positive re-stenosis</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Need of unplanned PCI in the treated stenosis or significant re-stenosis in the follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute coronary syndrome (ACS) and/or repeat revascularization</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late lumen loss/neointima thickness measured with OCT</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in minimal lumen area by OCT</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular systolic and diastolic function assessed by echocardiography</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery from endothelial damage, measured by high resolution ultrasound, after PCI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Non-invasive ultrasound over the radialis artery after the PCI procedure using Standard 6-7F guiding catheters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma markers of endothelial activation i.e., E-Selectin, VCAM-1, ICAM-1, nitrotyrosine levels</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma markers of inflammation i.e., CRP, IL-1β, IL-6 and IL-8.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma markers of matrix remodeling enzymes i.e., MMP-2 and MMP9</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating endothelial progenitor cells</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression (Affymetrix) e.g., transcription factors of sirtuins (SIRT) and nitric oxide synthase (NOS)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Diabetes</condition>
  <condition>Restenosis</condition>
  <arm_group>
    <arm_group_label>Bydureon 2 mg Once Weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomised to Bydureon will be treated with Metformin 1g BID, and only receive 10U of Humulin kwickpen QD at bedtime, with no more up-titration of insulin during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humulin kwickpen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomised to the comparator group will be treated with Meformin 1g BID and Humulin kwickpen to reach a fP-glucose level of 6 mmol/l. For that reason patients will be instructed to increase the bedtime Insulin dose of 2-4U every third day until this goal is reached.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bydureon</intervention_name>
    <description>2 mg Once Weekly</description>
    <arm_group_label>Bydureon 2 mg Once Weekly</arm_group_label>
    <other_name>Exenatide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humulin kwickpen</intervention_name>
    <description>Humulin kwickpen 10U QD at bedtime</description>
    <arm_group_label>Bydureon 2 mg Once Weekly</arm_group_label>
    <arm_group_label>Humulin kwickpen</arm_group_label>
    <other_name>Insulin Aspart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 1g BID</description>
    <arm_group_label>Bydureon 2 mg Once Weekly</arm_group_label>
    <arm_group_label>Humulin kwickpen</arm_group_label>
    <other_name>Biguanide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients eligible for PCI with application of DES, due to ACS.

          2. Patients with known or newly diagnosed T2D (type 2 diabetes is diagnosed according to
             current WHO criteria or by the use of anti-diabetic drugs)

          3. Male and female subjects 18-80 years.

          4. HbA1c (accordingly to IFCC) 47 mmol/mol - 110 mmol/mol.

          5. Signed informed consent form.

        Exclusion Criteria:

          1. Type 1 diabetes (autoantibody positive).

          2. Any history of receiving GLP-1 analogues or dipeptidyl peptidase inhibitors within 6
             months

          3. Known severe heart failure, classified as NYHA 4.

          4. Active myocarditis; malfunctioning artificial heart valve.

          5. History of ventricular tachycardia within 3 months before study entry; second- or
             third-degree atrioventricular block.

          6. Supine systolic blood pressure &lt;85 mm Hg or &gt;200 mm Hg at screening.

          7. Primary renal impairment, creatinine clearance &lt; 45 ml/min if treated with metformin.

          8. Uncorrected hypokalemia or hyperkalemia (potassium &lt;3.5 mmol/l or &gt;5.5 mmol/l).

          9. Significant anemia (Hb &lt; 90 g/l)

         10. Severe gastrointestinal disease, including gastroparesis. As judged by the
             Investigator.

         11. Body mass index (BMI) &gt; 45 kg/m2.

         12. Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy in
             the previous 5 years. Patients with intraepithelial squamous cell carcinoma of the
             skin treated with topical 5FU and subjects with basal cell skin cancer are allowed to
             enter the trial.

         13. Females of child bearing potential who are pregnant, breast-feeding or intend to
             become pregnant.

         14. Current drug and alcohol abuse.

         15. History of acute or chronic pancreatitis

         16. Subjects considered by the Investigator to be unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Nyström</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Nyström, MD,PhD</last_name>
    <phone>+4686163211</phone>
    <email>thomas.nystrom@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nils Witt, MD, PhD</last_name>
    <phone>+4686163211</phone>
    <email>nils.witt@sodersjukhuset.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept of clinical science and education Karolinska Institutet Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <state>Other</state>
        <zip>11883</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Nyström, MD, PhD</last_name>
      <phone>+4686163211</phone>
      <email>thomas.nystrom@sodersjukhuset.se</email>
    </contact>
    <contact_backup>
      <last_name>Nils Witt, Md, PhD</last_name>
      <phone>+4686161000</phone>
    </contact_backup>
    <investigator>
      <last_name>Nils Witt, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irene Santos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Eriksson L, Saxelin R, Röhl S, Roy J, Caidahl K, Nyström T, Hedin U, Razuvaev A. Glucagon-Like Peptide-1 Receptor Activation Does not Affect Re-Endothelialization but Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Nondiabetic Model of Arterial Injury. J Vasc Res. 2015;52(1):41-52. doi: 10.1159/000381097. Epub 2015 May 7.</citation>
    <PMID>25966620</PMID>
  </results_reference>
  <results_reference>
    <citation>Erdogdu O, Eriksson L, Xu H, Sjöholm A, Zhang Q, Nyström T. Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. J Mol Endocrinol. 2013 Mar 18;50(2):229-41. doi: 10.1530/JME-12-0166. Print 2013 Apr.</citation>
    <PMID>23343509</PMID>
  </results_reference>
  <results_reference>
    <citation>Erdogdu O, Nathanson D, Sjöholm A, Nyström T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol. 2010 Aug 30;325(1-2):26-35. doi: 10.1016/j.mce.2010.04.022. Epub 2010 May 7.</citation>
    <PMID>20452396</PMID>
  </results_reference>
  <results_reference>
    <citation>Erdogdu Ö, Eriksson L, Nyström T, Sjöholm Å, Zhang Q. Exendin-4 restores glucolipotoxicity-induced gene expression in human coronary artery endothelial cells. Biochem Biophys Res Commun. 2012 Mar 23;419(4):790-5. doi: 10.1016/j.bbrc.2012.02.106. Epub 2012 Feb 27.</citation>
    <PMID>22390929</PMID>
  </results_reference>
  <results_reference>
    <citation>Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004 Dec;287(6):E1209-15. Epub 2004 Sep 7.</citation>
    <PMID>15353407</PMID>
  </results_reference>
  <results_reference>
    <citation>Dokken BB, Piermarini CV, Teachey MK, Gura MT, Dameff CJ, Heller BD, Krate J, Ashgar AM, Querin L, Mitchell JL, Hilwig RW, Kern KB. Glucagon-like peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: potential antioxidant effects. Am J Physiol Heart Circ Physiol. 2013 Feb 15;304(4):H538-46. doi: 10.1152/ajpheart.00282.2012. Epub 2012 Dec 15.</citation>
    <PMID>23241323</PMID>
  </results_reference>
  <results_reference>
    <citation>Guagliumi G, Sirbu V, Bezerra H, Biondi-Zoccai G, Fiocca L, Musumeci G, Matiashvili A, Lortkipanidze N, Tahara S, Valsecchi O, Costa M. Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study. JACC Cardiovasc Interv. 2010 Jun;3(6):680-7. doi: 10.1016/j.jcin.2010.04.005.</citation>
    <PMID>20630463</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Thomas Nystrom</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Glucagon-like peptide-1</keyword>
  <keyword>Endothelialization</keyword>
  <keyword>Cardiac Function</keyword>
  <keyword>Exenatide</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

